Home > Dermatology > SPIN 2022 > IMIDs in Adults and Children: New Developments > No adverse pregnancy outcomes in patients exposed to baricitinib

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference
SPIN 2022
Doi
https://doi.org/10.55788/3f9a9e76
Atopic dermatitis and alopecia areata may present in women of childbearing age. Therefore, data on unintentional exposure during pregnancy is important. According to an analysis of a pharmacovigilance system, pregnancies with reported exposure to the JAK inhibitor baricitinib showed similar clinical outcomes compared with pregnancies in the general population. All JAK inhibitors are contraindicated during pregnancy, and women of childbearing age should use effective contraception. But many pregnancies are not recognised in time to avoid drug exposure. Therefore, an analysis of phase 3 randomised-controlled trials (RCTs) and post-marketing sources, including the use of baricitinib in rheumatoid arthritis, alopecia areata, and atopic dermatitis during pregnancy, was performed to shed some light on a possible deleterious effect [1]. All pregnancy events identified in RCTs and post-marketing sources, including spontaneous reports to the global Lilly pharmacov...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on